Safety of Fertility Treatments in Women With Systemic Lupus Erythematosus: Data From a Prospective Population‐Based Study

ABSTRACT Objective To assess safety of fertility treatments in women with systemic lupus erythematosus (SLE). Design Data from the multicentre French observational GR2 (Groupe de Recherche sur la Grossesse et les Maladies Rares) study (2014‐ongoing). Setting Seventy‐six centres in France. Population...

Full description

Saved in:
Bibliographic Details
Published inBJOG : an international journal of obstetrics and gynaecology Vol. 132; no. 5; pp. 614 - 624
Main Authors Dernoncourt, Amandine, Guettrot‐Imbert, Gaëlle, Sentilhes, Loïc, Molto, Anna, Queyrel‐Moranne, Viviane, Besnerais, Maelle Le, Lazaro, Estibaliz, Tieulié, Nathalie, Richez, Christophe, Hachulla, Eric, Sarrot‐Reynauld, Françoise, Leroux, Gaëlle, Orquevaux, Pauline, London, Jonathan, Sailler, Laurent, Souchaud‐Debouverie, Odile, Smets, Perrine, Godeau, Bertrand, Pannier, Emmanuelle, Murarasu, Anne, Berezne, Alice, Goulenok, Tiphaine, Morel, Nathalie, Mouthon, Luc, Duhaut, Pierre, Guern, Véronique Le, Costedoat‐Chalumeau, Nathalie, Alexandra, Audemard‐Verger, Antoine, Baudet, Rakiba, Belkhir, Ygal, Benhamou, Sabine, Berthier, Holy, Bezanahary, Boris, Bienvenu, Julien, Campagne, Jérémy, Chatelais, Emmanuel, Chatelus, Elodie, Chauvet, Fleur, Cohen, Céline, Comparon, Marion, Couderc, Eric, Daugas, Mathilde, Menthon, Claire, Moreuil, Odile, Debouverie, Estelle, Delattre, Azeddine, Dellal, Alban, Deroux, Marine, Driessen, Isabelle, Durieu, Florence, Eboue, Olivier, Fain, Bruno, Fautrel, Nicole, Ferreira, Tiphaine, Goulenok, Philippe, Goupille, Claire, Grange, Constance, Guillaud‐Danis, Sabrina, Hamroun, Aurélie, Hummel, Laurence, Josselin‐Mahr, Noémie, Jourde‐Chiche, Vincent, Langlois, Céline, Lartigau Roussin, Christian, Lavigne, Nicolas, Limal, Matthieu, Mahevas, Hélène, Maillard, Hubert, Marotte, Nicolas, Martin Silva, Agathe, Masseau, François, Maurier, Arsène, Mekinian, Martin, Michaud, Olivier, Moranne, Chafika, Morati‐Hafsaoui, Nathalie, Morel, Guillaume, Moulis, Luc, Mouthon, Barbara, Nicolas, Rodérau, Outh, Elisabeth, Pasquier, Laurent, Perard, Hélène, Petit‐Bauer, Evangeline, Pillebout, Vincent, Poindron, Xavier, Puechal, Gregory, Pugnet, Viviane, Queyrel‐Moranne, Loic, Raffray, Alexis, Regent, Nicolas, Schleinitz, Raphaele, Seror, Aude, Servais, Vincent, Sobanski, Martin, Soubrier, Thierry, Thomas, Nathalie, Tieulié, Geoffrey, Urbanski, Emmanuelle, Weber
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.04.2025
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:ABSTRACT Objective To assess safety of fertility treatments in women with systemic lupus erythematosus (SLE). Design Data from the multicentre French observational GR2 (Groupe de Recherche sur la Grossesse et les Maladies Rares) study (2014‐ongoing). Setting Seventy‐six centres in France. Population All pregnancies in women with SLE enrolled in the GR2 study, conceived before 1 August 2022, with available end‐of‐pregnancy data and known conception type, were included; that is, 577 spontaneous and 53 assisted pregnancies. Methods A comparative analysis of spontaneous and assisted pregnancies was conducted. Logistic regression was used to determine if fertility treatments were independently associated with live birth prognosis, adjusting for confounders (e.g., maternal age). Kaplan–Meier analysis compared cumulative incidences of disease flares and adverse pregnancy outcomes (APOs), with confounding factors adjusted using a Cox regression model. Main Outcome Measures Live birth, disease flares, and APOs. Results The mean age was older (35.8 vs. 32.3 years, p < 1 × 10−4), and twins were more frequent in assisted pregnancies (5/50, 10.0% vs. 20/554, 3.6%; p = 0.047). Lupus disease was clinically inactive at baseline in 51 (96.2%) assisted pregnancies (vs. n = 511, 89.6%; p = 0.15), with 35 of 45 (77.8%) having no chronic damage (vs. 448/513, 87.3%; p = 0.07). The live birth rate was similar between assisted and spontaneous pregnancies (n = 46, 86.8% vs. n = 505, 87.5%; p = 0.83), with no statistical difference in the incidence of lupus flares and APOs. These results remained consistent after adjusting for confounding factors. Conclusions Fertility treatments in women with mostly well‐controlled SLE did not appear to increase risks of maternal and neonatal complications, supporting current recommendations. Trial Registration ClinicalTrials.gov identifier: NCT02450396
Bibliography:Funding
The GR2 study was supported by Lupus France, Association des Sclérodermiques de France, Association Française du Gougerot Sjögren et des Syndromes Secs, Association francophone contre la Polychondrite atrophiante, AFM Téléthon, the French Society of Internal Medicine and Rheumatology, Cochin Hospital, the French Health Ministry, FOREUM, Association Prix Véronique Roualet, and UCB.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:1470-0328
1471-0528
1471-0528
DOI:10.1111/1471-0528.18050